Business
Hoth Therapeutics Announces the Appointment of Dr. William Weglicki, M.D. to Scientific Advisory Board
NEW YORK, Dec. 17, 2019 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), ("HOTH" or the "Company"), a biopharmaceutical company focused on developing
About this update from Hoth Therapeutics, Inc.
[{"type":"text","content":"NEW YORK, Dec. 17, 2019 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), (\"HOTH\" or the \"Company\"), a biopharmaceutical company focused on developing new generation therapies for dermatological disorders such as atopic dermatitis, chronic wounds, psoriasis and acne, today announced the addition of Dr. William Weglicki, M.D. to the Company's Scientific Advisory Board. While serving on the Board, Dr, Weglicki will oversee Hoth's Aprepitant Program under its Scientific Research Agreement with the George Washington University (\"GW\").\n\n \nMr. Robb Knie, CEO of Hoth Therapeutics, commented, \"I am pleased to welcome Dr. Weglicki to our Scientific Advisory Board. Dr. Weglicki will be instrumental towards the advancement of our Aprepitant program. Hoth is fortunate to have such well-respected leaders providing their invaluable expertise and insight to each of our significant research and development initiatives.\"\nDr. Weglicki is Professor of Biochemistry and Molecular Medicine at the George Washington University School of Medicine. Dr Weglicki is a recipient of the Lifetime Achievement Award in Cardiovascular Science, Medicine and Surgery, The International Academy of Cardiovascular Sciences. After completing a medical residency at Georgetown University Hospital in 1964 he completed a Cardiology fellowship in 1966 at Duke University where he trained in clinical cardiac catheterization and pharmacology basic research. He was then appointed as a research associate at NIH's NICHHD and the McCollum Pratt Institute of the Johns Hopkins University where he studied the cardiac pathobiology of alpha tocopherol deficiency. In 1968 He joined Harvard's Peter Bent Brigham Hospital Department of Medicine's Cardiovascular Research unit, and rose from Instructor to Associate Professor in 1975. There he concentrated his research on the role of phospholipases of the heart in the ischemic perturbation of cardiac membrane phospholipids and organelles, which led to several RO1 NIH grant awards. With his research team he moved to the Medical College of Virginia/VCU in 1975 as chairman of the Department of Biophysics and served as a professor of Medicine (Cardiology); there he was active in teaching medical and mentoring graduate students, while publishing a series of manuscripts on cardiac lysosomal activity in myocardial ischemia and the d...